Correlation Between Lipoprotein-Related Phospholipase A2 and Metabolic Syndrome.

Lp-PLA2 and lipid profile cardiovascular risk lipoprotein metabolic syndrome

Journal

International journal of general medicine
ISSN: 1178-7074
Titre abrégé: Int J Gen Med
Pays: New Zealand
ID NLM: 101515487

Informations de publication

Date de publication:
2023
Historique:
received: 27 08 2023
accepted: 15 12 2023
medline: 27 12 2023
pubmed: 27 12 2023
entrez: 27 12 2023
Statut: epublish

Résumé

Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been recognized as a valuable biomarker for identifying the risk of cardiovascular diseases and inflammation. Furthermore, there is strong evidence to suggest that metabolic syndrome is closely associated with chronic inflammation. Accordingly, the present study endeavors to examine the potential correlation between metabolic syndrome and the levels of Lp-PLA2. To explore the relationship between Lp-PLA2 levels and metabolic syndrome, and to establish the predictive cut-off value of Lp-PLA2, a retrospective analysis was conducted using medical data from a sample of 3549 Chinese adults (comprising 2182 men and 1367 women) aged between 18 and 50 years, who had undergone health check-ups. In addition, the study also sought to investigate any potential differences in Lp-PLA2 levels based on sex and age. The analysis of the data indicated that participants had a mean age of 44.2 years, a mean Lp-PLA2 level of 589 IU/L, and a metabolic syndrome prevalence of 22%. Lp-PLA2 levels were significantly different between males and females, and a significant correlation was observed between Lp-PLA2 levels and clinical and metabolic characteristics, including BMI, cholesterol, and triglycerides. Interestingly, Lp-PLA2 demonstrated potential as an indicator of metabolic syndrome, particularly in females, despite other biomarkers, such as TG/HDL-C and WHR, exhibiting better area under the curve. Our findings suggest that Lp-PLA2 may serve as a useful biomarker for identifying individuals at risk of developing metabolic syndrome, particularly in females. Further research is needed to explore the potential of Lp-PLA2 as a diagnostic and therapeutic target for metabolic syndrome.

Sections du résumé

Background UNASSIGNED
Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been recognized as a valuable biomarker for identifying the risk of cardiovascular diseases and inflammation. Furthermore, there is strong evidence to suggest that metabolic syndrome is closely associated with chronic inflammation. Accordingly, the present study endeavors to examine the potential correlation between metabolic syndrome and the levels of Lp-PLA2.
Methods UNASSIGNED
To explore the relationship between Lp-PLA2 levels and metabolic syndrome, and to establish the predictive cut-off value of Lp-PLA2, a retrospective analysis was conducted using medical data from a sample of 3549 Chinese adults (comprising 2182 men and 1367 women) aged between 18 and 50 years, who had undergone health check-ups. In addition, the study also sought to investigate any potential differences in Lp-PLA2 levels based on sex and age.
Results UNASSIGNED
The analysis of the data indicated that participants had a mean age of 44.2 years, a mean Lp-PLA2 level of 589 IU/L, and a metabolic syndrome prevalence of 22%. Lp-PLA2 levels were significantly different between males and females, and a significant correlation was observed between Lp-PLA2 levels and clinical and metabolic characteristics, including BMI, cholesterol, and triglycerides. Interestingly, Lp-PLA2 demonstrated potential as an indicator of metabolic syndrome, particularly in females, despite other biomarkers, such as TG/HDL-C and WHR, exhibiting better area under the curve.
Conclusion UNASSIGNED
Our findings suggest that Lp-PLA2 may serve as a useful biomarker for identifying individuals at risk of developing metabolic syndrome, particularly in females. Further research is needed to explore the potential of Lp-PLA2 as a diagnostic and therapeutic target for metabolic syndrome.

Identifiants

pubmed: 38148886
doi: 10.2147/IJGM.S437397
pii: 437397
pmc: PMC10750477
doi:

Types de publication

Journal Article

Langues

eng

Pagination

6041-6049

Informations de copyright

© 2023 Wang et al.

Déclaration de conflit d'intérêts

All authors declare that they have no conflicts of interest.

Auteurs

Kai-Yu Wang (KY)

Department of Family Medicine, Chang-Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.

Yi-Chuan Chen (YC)

Department of Family Medicine, Chang-Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.
College of Medicine, Chang Gung University, Taoyuan, Taiwan.

Jau-Yuan Chen (JY)

Department of Family Medicine, Chang-Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.
College of Medicine, Chang Gung University, Taoyuan, Taiwan.

Song-Seng Loke (SS)

Department of Family Medicine, Chang-Gung Memorial Hospital at Kaohsiung, Kaohsiung, Taiwan.

Wei-Chung Yeh (WC)

Department of Family Medicine, Chang-Gung Memorial Hospital at Keelung, Keelung, Taiwan.

Wen-Cheng Li (WC)

Department of Family Medicine, Chang-Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.
College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Department of Health Management, Xiamen Chang-Gung Hospital, Xiamen, People's Republic of China.

Classifications MeSH